Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 19/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12934940 | 0.89 | CXCR4 (0.53) | CXCR4CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL30051648 | 0.85 | CXCR4 (0.62) | CXCR4CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL2085276 | 0.85 | CXCR4 (0.62) | CXCR4CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL4214957 | 0.83 | CXCR4 (0.61) | CXCR4CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL12934991 | 0.81 | CXCR4 (0.53) | CXCR4CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL23428717 | 0.80 | EGLN1 (0.41) | CXCR4CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL2080491 | 0.79 | CXCR4 (0.56) | CXCR4CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL12934917 | 0.79 | CXCR4 (0.51) | CXCR4CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL12934949 | 0.78 | CXCR4 (0.55) | CXCR4CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL12934952 | 0.78 | CXCR4 (0.55) | CXCR4CHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613613-B1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORP (US) | 2021-06-02 | — | — | EP | disclosed |
| US-7863293-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863293-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| EP-1613613-A4 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC (CA) | 2009-03-25 | — | — | EP | disclosed |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED CORPORATION (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED CORPORATION (CA) | 2008-10-16 | — | — | US | disclosed |
| US-7291631-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291631-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1613613-A2 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004091518-A2 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | CXCR4, CXCR1, CXCR3 | CXCR4 1/4885CHRM2 655/4885CHRM4 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.